









市場行情
/
股票
/
nasdaq-mirm
/

Mirum Pharmaceuticals Inc

MIRM

79.434USD

-1.316-1.63%

交易中（美東）報價延遲15分鐘

4.08B總市值

虧損本益比TTM



Mirum Pharmaceuticals Inc

79.434

-1.316-1.63%

概覽公司財務分析

概覽

公司

財務

分析

關於 Mirum Pharmaceuticals Inc 公司

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Mirum Pharmaceuticals Inc簡介



公司代碼MIRM

公司名稱Mirum Pharmaceuticals Inc

上市日期Jul 18, 2019

CEOPeetz (Christopher)

員工數量322

證券類型Ordinary Share

年結日Jul 18

公司地址989 East Hillsdale Boulevard, Suite 300

城市FOSTER CITY

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94404

電話16506674085

網址https://mirumpharma.com/

公司代碼MIRM

上市日期Jul 18, 2019

CEOPeetz (Christopher)

Mirum Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Christopher (Chris) Peetz

Chief Executive Officer, Co-Founder, Director

366.34K

+5.51%

Mr. Michael G. (Mike) Grey

Independent Chairman of the Board

280.16K

Ms. Lara Longpre

Chief Development Officer

104.41K

-0.80%

Dr. Pamela Vig, Ph.D.

Chief Scientific Officer, Head of Research

103.78K

Mr. Eric H. Bjerkholt

Chief Financial Officer

39.66K

+28.33%

Mr. Peter Radovich

President, Chief Operating Officer

18.67K

-30.74%

Ms. Laura A. Brege

Independent Director

15.70K

Mr. Patrick J. Heron

Independent Director

5.70K

Dr. Joanne Quan, M.D.

Chief Medical Officer

5.65K

Mr. Andrew Mckibben

Investor Relations

名稱

名稱/職務

職務

持股

持股變動

Mr. Christopher (Chris) Peetz

Chief Executive Officer, Co-Founder, Director

366.34K

+5.51%

Mr. Michael G. (Mike) Grey

Independent Chairman of the Board

280.16K

Ms. Lara Longpre

Chief Development Officer

104.41K

-0.80%

Dr. Pamela Vig, Ph.D.

Chief Scientific Officer, Head of Research

103.78K

Mr. Eric H. Bjerkholt

Chief Financial Officer

39.66K

+28.33%

Mr. Peter Radovich

President, Chief Operating Officer

18.67K

-30.74%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

業務USD

名稱

營收

佔比

Livmarli

88.16M

68.99%

Bile Acid Medicines

39.63M

31.01%

License and other revenue

0.00

0.00%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Livmarli

88.16M

68.99%

Bile Acid Medicines

39.63M

31.01%

License and other revenue

0.00

0.00%

股東統計

更新時間: 11月19日週三

持股股東

股東類型

持股股東

佔比

Frazier Life Sciences Management, L.P.

13.15%

Janus Henderson Investors

9.67%

BlackRock Institutional Trust Company, N.A.

5.87%

The Vanguard Group, Inc.

4.91%

Eventide Asset Management, LLC

4.88%

其他

61.53%

持股股東

佔比

Frazier Life Sciences Management, L.P.

13.15%

Janus Henderson Investors

9.67%

BlackRock Institutional Trust Company, N.A.

5.87%

The Vanguard Group, Inc.

4.91%

Eventide Asset Management, LLC

4.88%

其他

61.53%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

35.46%

Investment Advisor

34.76%

Hedge Fund

20.79%

Private Equity

13.59%

Research Firm

4.99%

Venture Capital

2.45%

Individual Investor

1.66%

Pension Fund

0.90%

Bank and Trust

0.25%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

468

57.20M

111.61%

-6.92M

2025Q2

458

58.36M

116.21%

-4.59M

2025Q1

454

57.59M

116.38%

-4.84M

2024Q4

425

56.60M

115.52%

-10.44M

2024Q3

408

56.58M

118.52%

-12.05M

2024Q2

398

57.22M

121.33%

-10.51M

2024Q1

391

57.27M

121.82%

-5.03M

2023Q4

376

54.05M

116.10%

-4.66M

2023Q3

337

55.34M

123.03%

+4.03M

2023Q2

315

43.67M

117.43%

-6.40M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Frazier Life Sciences Management, L.P.

6.80M

13.53%

Aug 18, 2025

Janus Henderson Investors

5.24M

10.42%

+154.32K

+3.04%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.10M

6.18%

+88.20K

+2.92%

Jun 30, 2025

The Vanguard Group, Inc.

2.56M

5.09%

+23.77K

+0.94%

Jun 30, 2025

Eventide Asset Management, LLC

2.64M

5.25%

+110.48K

+4.37%

Jun 30, 2025

BVF Partners L.P.

2.76M

5.5%

-35.18K

-1.26%

Jun 30, 2025

State Street Investment Management (US)

1.38M

2.74%

-118.94K

-7.96%

Jun 30, 2025

Novo Holdings A/S

1.50M

2.99%

+55.00

+0.00%

Jun 30, 2025

T. Rowe Price Associates, Inc.

1.38M

2.75%

-2.14K

-0.16%

Jun 30, 2025

Tang Capital Management, LLC

1.24M

2.46%

-1.08K

-0.09%

Jun 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

Virtus LifeSci Biotech Products ETF

2.37%

Invesco Dorsey Wright Healthcare Momentum ETF

1.52%

ALPS Medical Breakthroughs ETF

1.51%

Federated Hermes MDT Small Cap Core ETF

1.14%

First Trust Innovation Leaders ETF

1.03%

Tema Heart & Health ETF

1.02%

First Trust Small Cap Growth AlphaDEX Fund

0.68%

State Street SPDR S&P Biotech ETF

0.58%

First Trust NASDAQ Pharmaceuticals ETF

0.52%

JPMorgan Fundamental Data Science Small Core ETF

0.43%

Virtus LifeSci Biotech Products ETF

佔比2.37%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比1.52%

ALPS Medical Breakthroughs ETF

佔比1.51%

Federated Hermes MDT Small Cap Core ETF

佔比1.14%

First Trust Innovation Leaders ETF

佔比1.03%

Tema Heart & Health ETF

佔比1.02%

First Trust Small Cap Growth AlphaDEX Fund

佔比0.68%

State Street SPDR S&P Biotech ETF

佔比0.58%

First Trust NASDAQ Pharmaceuticals ETF

佔比0.52%

JPMorgan Fundamental Data Science Small Core ETF

佔比0.43%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Mirum Pharmaceuticals Inc的前五大股東是誰？



Mirum Pharmaceuticals Inc的前五大股東如下：
Frazier Life Sciences Management, L.P.
持有股份：6.80M
佔總股份比例：13.53%。
Janus Henderson Investors
持有股份：5.24M
佔總股份比例：10.42%。
BlackRock Institutional Trust Company, N.A.
持有股份：3.10M
佔總股份比例：6.18%。
The Vanguard Group, Inc.
持有股份：2.56M
佔總股份比例：5.09%。
Eventide Asset Management, LLC
持有股份：2.64M
佔總股份比例：5.25%。